Pfizer Forays into ADHD Market by Exercising Option to Acquire NextWave Pharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 11 (Table of Contents)
Published: 8 Nov-2012
DOI: 10.3833/pdr.v2012.i11.1832 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a deal worth up to US$680 M, Pfizer is to acquire NextWave Pharmaceuticals, a speciality pharmaceutical company that won US FDA approval in September 2012 for Quillivant XR™ (methylphenidate hydrochloride), a once-daily, extended-release formulation of liquid methylphenidate for attention deficit hyperactivity disorder that was developed using Tris Pharma’s OralXR+™ drug delivery platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS